scholarly journals SARS‐CoV‐2 spike glycoprotein‐binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection

FEBS Letters ◽  
2020 ◽  
Vol 594 (11) ◽  
pp. 1651-1660 ◽  
Author(s):  
Kourosh Honarmand Ebrahimi
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Binding Proteins ◽  
Upper Respiratory Tract ◽  
Spike Glycoprotein ◽  
Upper Respiratory

scholarly journals Route of Nutrition Influences Generation of Antibody-Forming Cells and Initial Defense to an Active Viral Infection in the Upper Respiratory Tract

2003 ◽  
Vol 237 (4) ◽  
pp. 565-573 ◽  
Author(s):  
Cheryl D. Johnson ◽  
Kenneth A. Kudsk ◽  
Kazuhiko Fukatsu ◽  
Kathryn B. Renegar ◽  
Ben L. Zarzaur
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

scholarly journals Spectrum of Influenza B Viral Infection in Indian Children: A Tertiary Centre Experience

2018 ◽  
Vol 38 (3) ◽  
pp. 170-175 ◽  
Author(s):  
Sandesh Kini ◽  
Ramesh Bhat Y ◽  
Koushik Handattu ◽  
Phalguna Kousika ◽  
Chennakeshava Thunga
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Viral Infection ◽  
Respiratory Tract Infection ◽  
Severe Pneumonia ◽  
Upper Respiratory Tract Infection ◽  
Influenza B Virus ◽  
Influenza B ◽  
Upper Respiratory Tract ◽  
Upper Respiratory

Introduction: Influenza viral infection in children can range from subclinical illness to multi system involvement. The morbidity associated with influenza B viral infection is often overlooked. India being the second most populous country, accounts for 20% of global childhood deaths from respiratory infections. There is paucity of data on the clinical features and complications of influenza B viral infections in children from the Indian subcontinent. Our objective was to study the clinical profile, seasonality, complications and outcome associated with Influenza B viral infection in children < 18 years of age. Material and Methods: We conducted a retrospective observational study at a tertiary care hospital in South India. Children less than 18 years of age admitted to our paediatric unit were included in the study. We reviewed the case sheets of 56 patients who tested positive for influenza B virus during the study period and recorded their clinical and laboratory data. Throat swab obtained from cases were tested by RT-PCR. The illness was classified as upper respiratory tract infection, pneumonia and severe pneumonia. Outcome measures analysed were- mortality, need for oxygen supplementation or assisted ventilation, duration of oxygen support, duration of ICU/ hospital stay and time for defervescence following initiation of oseltamivir therapy. Results: The mean age of the study population was 6.98 years. Majority of the affected children were > 5 years of age in the school going category with a male to female ratio of 3:2. The diagnosis based on clinical and radiological findings included upper respiratory tract infection (URTI) in 44 (78.5%) cases followed by pneumonia in 11(19.6%) and severe pneumonia in one (1.7%) child. The peak incidence was in the month of March. Malnutrition was the most common risk factor affecting 22 (39.3%) cases followed by history of asthma in eight (14.3%). Three children required oxygen supplementation at admission. The median duration of hospital stay was seven days. The median duration for defervescence following initiation of oseltamivir therapy was 24 hours. Mortality was recorded in one infant who died of acute respiratory distress syndrome. Conclusions: Influenza B virus should be screened in all children having underlying high risk medical condition, presenting with pneumonia or upper respiratory tract infection. Oseltamivir therapy should be initiated early in the management of influenza B viral infections to prevent complications.

scholarly journals Time-course of upper respiratory tract viral infection and COPD exacerbation

2019 ◽  
Vol 54 (4) ◽  
pp. 1900407 ◽  
Author(s):  
Daiana Stolz ◽  
Eleni Papakonstantinou ◽  
Leticia Grize ◽  
Daniel Schilter ◽  
Werner Strobel ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Respiratory Tract Infections ◽  
Viral Infections ◽  
Nucleic Acid Amplification ◽  
Chronic Obstructive ◽  
Upper Respiratory Tract ◽  
Stable Period ◽  
Upper Respiratory ◽  
Tract Infections

Viral respiratory tract infections have been implicated as the predominant risk factor for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). We aimed to evaluate, longitudinally, the association between upper respiratory tract infections (URTI) caused by viruses and AECOPD.Detection of 18 viruses was performed in naso- and orοpharyngeal swabs from 450 COPD patients (Global Initiative for Chronic Obstructive Lung Disease stages 2–4) who were followed for a mean of 27 months. Swabs were taken during stable periods (n=1909), at URTI onset (n=391), 10 days after the URTI (n=356) and during an AECOPD (n=177) and tested using a multiplex nucleic acid amplification test.Evidence of at least one respiratory virus was significantly higher at URTI onset (52.7%), 10 days after the URTI (15.2%) and during an AECOPD (38.4%), compared with the stable period (5.3%, p<0.001). During stable visits, rhinovirus accounted for 54.2% of all viral infections, followed by coronavirus (20.5%). None of the viruses were identified in two consecutive stable visits. Patients with a viral infection at URTI onset did not have a higher incidence of exacerbation than patients without viral infection (p=0.993). Τhe incidence of any viral infection during an AECOPD was similar between URTI-related AECOPD and non-URTI-related AECOPD (p=0.359). Only 24% of the patients that had a URTI-related AECOPD had the same virus at URTI onset and during an AECOPD. Detection of parainfluenza 3 at URTI onset was associated with a higher risk of an AECOPD (p=0.003). Rhinovirus and coronavirus were the most frequently detected viruses during AECOPD visits, accounting for 35.7% and 25.9% of all viral infections, respectively.The prevalence of viral infection during the stable period of COPD was low. The risk of exacerbation following the onset of URTI symptoms depends on the particular virus associated with the event and was significant only for parainfluenza 3.

scholarly journals Frequency of Detection of Upper Respiratory Tract Viruses in Patients Tested for Pandemic H1N1/09 Viral Infection

2010 ◽  
Vol 48 (9) ◽  
pp. 3383-3385 ◽  
Author(s):  
C. Nisii ◽  
S. Meschi ◽  
M. Selleri ◽  
L. Bordi ◽  
C. Castilletti ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Pandemic H1n1 ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Respiratory Tract Viruses

scholarly journals Experience of the use of combined phytopreparations in the treatment of respiratory tract diseases

2018 ◽  
Vol 22 (1) ◽  
pp. 46-50
Author(s):  
V.M. Dudnyk ◽  
I.V. Моrozova ◽  
M.O. Shalamai ◽  
Y.V. Vyzhga
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Integrated Management ◽  
Age Groups ◽  
Clinical Effectiveness ◽  
Main Group ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Modern Approach ◽  
Upper Respiratory

The article showed the problem of integrated management of children different age groups with upper respiratory tract viral infection. It reflected modern approach of using multicomponent herbal medicine for cough therapy in children in the practice of pediatrician. We evaluated necessity of the prescription and effect of the herbal drug in syrup type Gamma in case of acute respiratory diseases in 50 children, from the age of 2 up to 15 years of life, that were treated at infectious-diagnostic department of Vinnytsya regional children’s hospital and had cough symptom. Analysis of the results of the use of herbal multicomponent Gamma syrup in children with cough was provided. The duration of the cough period, qualitative changes in the cough symptom, such as frequency and expectoration of sputum were analyzed. In every case we estimated time of cough originating, changes of its characteristics from the dry to productive, decreasing of the intensity and time of the clinical recovering. The effectiveness of Gamma syrup was evaluated by comparing the main group of patients and the control group. In 92% of patients in the main group on day 7 cough completely stopped, comparing to the control group –cough stopped in 52%. This is the evidence of positive effect on cough, sputum discharge, it`s viscosity and common improvement of drainage function respiratory tract. Using of herbal multicomponent Gamma syrup shows high clinical effectiveness as mucolytic, broncholytic, expectorant and anti-inflammatory drug in children with cough in complex treatment of upper respiratory tract viral infection.

scholarly journals Efficacy and safety of Aviron Rapid® in 18-60-year-old patients with clinical diagnosis of acute respiratory viral infection: a multicenter, randomized, double-blind, placebo-controlled clinical trial

Folia Medica ◽  
2021 ◽  
Vol 63 (1) ◽  
pp. 129-137
Author(s):  
Georgi Popov ◽  
Margarita Gospodinova-Bliznakova ◽  
Zlatko Kalvatchev ◽  
Andrey Tchorbanov
Keyword(s):  
Respiratory Tract ◽  
Viral Infection ◽  
Clinical Diagnosis ◽  
Symptomatic Therapy ◽  
Upper Respiratory Tract ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Duration Of Disease ◽  
Upper Respiratory ◽  
Tract Infections

Aim: Prevention and treatment of upper respiratory tract infections are given the highest priority because of the tremendous health and economic impact of these diseases. Development of novel effective and safe options for treatment can contribute considerably to decrease the burden of disease. Materials and methods: We designed a multicenter, randomized, double-blind, placebo-controlled study in ambulatory-treated adult patients with a clinical diagnosis of acute upper respiratory tract viral infection. The patients (18-60 years old) were randomized into two groups and followed-up for 5 days. Group 1 received the standard symptomatic therapy + Aviron Rapid&reg;, and Group 2 received the standard symptomatic therapy + placebo. The primary endpoint of the study was defined as the duration of disease measured by the percentages of disease-free patients for every 12-hour period of the study.&nbsp; Results: Treating clinically relevant patients with the natural product Aviron Rapid&reg; for 5 days decreases the duration of disease, the intake of antipyretics and the severity of symptoms. Significant difference between the tested groups for most of studied parameters was found as soon as 12 or 24 hours after initiation of administration in favour of active arm and was the most prominent on days 3 and 4. Significant decrease in the total score of symptoms severity was achieved on day 4 and extended to the end of study. There were no dif-ferences in the adverse events between the groups and the tested product demonstrated excellent safety profile.&nbsp; Conclusions: This study is a clinical confirmation of well documented antiviral activity of the product targeting multiple points in viral replication and covering broad spectrum viral pathogens.

Sign in / Sign up

Export Citation Format

Share Document